The American Academy of Ophthalmology and Verana Health Accelerate Clinical Trials for Patients with Rare, Sight-Threatening Retinal Diseases Through Verana Trial Connect

Verana Trial Connect Now Facilitates No-cost Genetic Testing and Counseling for Patients with Inherited Retinal Diseases

San Francisco, California – October 9, 2019 – The American Academy of Ophthalmology (AAO) and Verana Health today announced that they are now facilitating no-cost genetic testing and counseling for patients with certain inherited retinal diseases through Verana Trial Connect, a powerful cloud-based application that facilitates physician and patient awareness of clinical trial opportunities. Leveraging the information found in the largest specialty clinical database in medicine—the American Academy of Ophthalmology IRIS® Registry (Intelligent Research In Sight), Verana Trial Connect aims to accelerate trial enrollment and, with the addition of genetic screening and counseling, now has the potential to open up new options to patients for whom limited or no treatments exist. Verana Trial Connect will initially enable genetic screening and counseling at no cost for select conditions, and later will expand to include patients with other inherited retinal conditions. 

Patients with inherited retinal diseases—approximately 200,000 individuals in the United States—are often significantly visually impaired and lack treatment options. Currently, there are more than 50 novel therapies in development for these patients; however, patient trial recruitment remains the greatest barrier to drug development. Genetic testing and counseling may open up access to clinical trials and promising new therapies for this underserved population. 

“Through this new offering, the Academy and Verana are providing new opportunities for physicians to not only better serve their patients, but to engage in research that may ultimately lead to groundbreaking therapies for rare and sight-threatening ophthalmic diseases,” said David W. Parke, II, MD, CEO, of the American Academy of Ophthalmology. “This is a very challenging area where disease prevalence is low and awareness of clinical trials and available treatment options is limited among physicians and patients alike. By enabling ophthalmologists to provide access to genetic screening and counseling at no cost, we can help physicians identify patients who could benefit from participation in a clinical trial.” 

“We’re excited to continue to collaborate with the American Academy of Ophthalmology to advance care for patients through the Academy’s IRIS Registry,” said Miki Kapoor, CEO of Verana Health. “Just last month, we launched Verana Practice Insights, an important tool that empowers physicians to advance patient care through critical data insights. Now through this new program, we will be able to enhance the IRIS Registry with genetic information using Verana Trial Connect, while facilitating study enrollment opportunities for patients who traditionally have been difficult to identify.” 

Physicians can also learn more about Verana Trial Connect and Verana Practice Insights at AAO 2019, which is being held October 11-15 in San Francisco, by visiting Verana booth #2047, registering for the AAO course “Member Value Tools From the IRIS Registry and Verana Health: How to Improve Your Practice,” or attending the Technology Pavilion presentation “Big Data, Better Insights: How the IRIS Registry and Verana are Transforming Practice Intelligence.” 

About the American Academy of Ophthalmology

The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit

About Verana Health

Verana Health is a technology company assembling the largest clinical databases in medicine. Verana Health utilizes this real-world data to derive clinical and business insights for physicians and life science companies through its regulatory-grade data platform. By activating this vast amount of data, Verana Health can learn from the collective experience of millions of individual patients to empower physicians and accelerate research for patients. Learn more at

Media Contacts:
Verana Health
Michele Gray
Gray Communications, llc.
[email protected]

American Academy of Ophthalmology
Media Relations
[email protected]

Verana Health Logo

Let's Accelerate Research Together

To learn more about Verana Health, please fill out the information below and our team will follow up with you as soon as possible.